Loading...

MLTX MOONLAKE IMMUNOTHERAPEUTICS Investments/Divestments 8-K Filing

MNLK

MLTX

MOONLAKE IMMUNOTHERAPEUTICS

(MLTX)

2024 8-K

Show Summary

Summary

Financial Statements

Investor Meetings

Financial Results

Financial Results

Investor Presentation

Financial Results Announcement

FDA and EMA Positive Feedba...

Annual General Meeting

Earnings Report

Financial Results Announcement

Regulatory Approval

Financial Results Announcement

Phase 2 Trial Results

Filing with Quantitative Data

Compensation Increases

Financial Results Announcement

Underwriting Agreement and ...

Annual General Meeting

Quantitative Data

Quantitative Data

Financial Results Announcement

External Links:

MoonLake Immunotherapeutics announces positive feedback from FDA and EMA on its Phase 2 interactions for advancing its Phase 3 program in psoriatic arthritis.

AI Assistant

MOONLAKE IMMUNOTHERAPEUTICS

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.